APOE and Alzheimer disease: Thus, developing AD therapies that directly target specific APOE lipoproteins rather than indirectly affecting the downstream effects of APOE will more definitively quantitate the magnitude of APOE-mediated detriments attributable to allelic variations in the presence of comorbidities.